Does treatment with rosiglitazone result in improved pancreatic beta-cell function as compared to glimepiride in metformin treated diabetes type 2 patients?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON27919

Enrollment

Registered

2006-02-07

Start date

2004-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes is a heterogeneous disorder involving varying levels of insulin insensitivity and impaired islet beta-cell function.

Interventions

Patients will be randomized to 26 weeks of treatment with metformin with glimepiride 4 mg a day or metformin with rosiglitazone 8 mg a day. Before the start of the treatment patients will undergo a 2

Eligibility

Inclusion criteria

Inclusion criteria: 1. Informed consent form signed; 2. Type 2 diabetes patients, accoring to WHO criteria; 3. Age 18-70 years; 4. Use of metformin, at least 500 mg a day; 5. HbA1c > 7.0% inclusive when on metformin alone, or > 6.5 % when on combination therapy of metformin and a sulfonylureumderivative. Use of a sulfonylureumderivative is allowed, with a wash-out period of four weeks before the first assessments.

Exclusion criteria

Exclusion criteria: 1. Established coronary heart disease; 2. Previous use of a thiazolidinedione.

Design outcomes

Primary

Measure	Time frame
The peak insulin concentrations during the hyperglycaemic clamp protocol.	—

Contacts

Public ContactS.G.H.A. Swinnen

Academic Medical Center, Department of Internal Medicine F4-257, P.O. box 22660

S.G.Swinnen@amc.uva.nl+31 (0)20 5667836

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)